Sage rejects Biogen's takeover offer, to explore strategic alternatives
Jan 27 (Reuters) - Sage Therapeutics SAGE.O said on Monday that its board has unanimously rejected the takeover offer it received from Biogen BIIB.O and added that its board of directors has initiated a process to explore strategic alternatives. (Reporting by Sneha S K; Editing by Tasim Zahid) ((Sneha.SK@thomsonreuters.com;))
Recent news on Sage Therapeutics
See all newsBrief: Supernus Pharmaceuticals Completes Acquisition Of Sage Therapeutics
Sage Therapeutics Inc Reports Results For The Quarter Ended June 30: Earnings Summary
SAGE Therapeutics Q2 revenue rises sequentially
Brief: Supernus Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Sage Therapeutics Tender Offer
Sage Therapeutics Inc Expected To Post A Loss Of 95 Cents A Share: Earnings Preview